Kintara Therapeutics Stock Is Trading Higher: What's Driving The Action?
Portfolio Pulse from Adam Eckert
Kintara Therapeutics Inc (NASDAQ:KTRA) has secured a $2 million grant from the National Institutes Of Health (NIH) to support the development of REM-001, a therapy for the treatment of cutaneous metastatic breast cancer. The funds will be used to restart the REM-001 program and gain clinical evidence to demonstrate proof of concept for the therapy platform. The news has led to a 19.7% increase in Kintara's stock price.
June 29, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kintara Therapeutics has received a $2 million grant from NIH for the development of REM-001, leading to a 19.7% increase in its stock price.
The grant from NIH is a significant financial boost for Kintara Therapeutics, which will support the development of its REM-001 therapy. This positive news has already resulted in a significant increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100